Drugs / Methotrexate (MTX)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07280156 | Dec 2025 → Dec 2027 expected | gout | Protalix | Recruiting | No outcome recorded |
| Phase 2 | NCT00671658 | Nov 2002 → Jul 2013 | acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methotrexate (MTX) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07280156 ↗ |
| Known as | MTX | “Methotrexate (MTX)” NCT07280156 ↗ |
| Route | Intrathecal | “Methotrexate (MTX) 12 mg intrathecally” NCT00671658 ↗ |